ClinicalTrials.gg
Not yet recruitingNCT06380348Updated Apr 23, 2024

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

A Phase 3 interventional study of JMT101 Injection and Osimertinib tablet in Local Advanced or Metastatic NSCLC, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
6th of 16
398 · median 365
Started
2024
with 2 others
Phase 3
7 of 17
6 open now
Primary completion
2027-03
later than 5 of 11 live
Registered
8th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in participants with local advanced or metastatic non-small-cell lung cancer harboured EGFR 20ins mutation without prior systemic therapy.

Primary objective of this study is to assess the efficacy of JMT101 combined with Osimertinib versus Cisplatin combined with pemetrexed using by (Independent Review Center)IRC-assessed Progression Free Survival (PFS) per RECIST 1.1 as primary endpoint. Approximately 398 participants are estimated to be randomized into the study. Participants enrolled will be randomized to JMT101 or Cisplatin chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without) and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 versus 1).

03

Conditions studied

  • Local Advanced or Metastatic NSCLC

Keywords

  • Harboring EGFR 20ins mutation
  • Without prior systemic therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18-75 years old.
  2. or cytologically confirmed diagnosis of NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the IASLC TNM staging criteria) or (Stage IV), not suitable for curative therapy. For central laboratory confirmation of EGFR exon 20 insertion mutation with tumour tissue/blood sample.
  3. At least 1 per Version 1.1
  4. ≥ 12 weeks
  5. (ECOG) performance status of 0 to 1
  6. Adequate organ and hematologic function

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any systemic anti-cancer therapy for locally advanced or NSCLC.
  2. Central nervous system metastasis with associated symptom and signs.
  3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.
  4. History of interstitial lung disease, or infectious pneumonitis need heavy antibiotics therapy
  5. As judged by the investigator, unsuitable for attending the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    JMT101 combined with Osimertinib

    Drug: JMT101 Injection · Drug: Osimertinib tablet

  • Active comparator
    Cisplatin combined with pemetrexed

    Participants randomized into chemotherapy arm can receive up to 4 cycles of pemetrexed + cisplatin (pemetrexed 500 mg/m\^2 + cisplatin 75mg/m\^2, IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.

    Drug: Cisplatin injection · Drug: Pemetrexed injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 35 months after the first participant is randomized

  2. Overall Response Rate (ORR) by IRC per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

  3. Duration of Response (DoR) by IRC per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

  4. PFS by investigator per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

  5. ORR by investigator per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

  6. DoR by investigator per RECIST 1.1

    Time frame: Up to approximately 35 months after the first participant is randomized

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Mar 2027, 35 months later.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 35 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 23, 2024
StartEst.
Apr 26, 2024
Primary completionEst.
Mar 26, 2027
CompletionEst.
Mar 26, 2028
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06380348
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Apr 26, 2024 (estimated)
Primary completion
Mar 26, 2027 (estimated)
Completion
Mar 26, 2028 (estimated)
Last update
Apr 23, 2024

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@mail.ecspc.com
86-0311-69085587
Li Zhang, M.D.
principal investigator · Cancer Prevention and Treatment Center of Sun Yat sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug

Start the discussion